Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019048423) L-SERINE SUPPLEMENTATION IN SUBJECTS WITH PRE-DIABETES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/048423 International Application No.: PCT/EP2018/073723
Publication Date: 14.03.2019 International Filing Date: 04.09.2018
IPC:
A61K 31/198 (2006.01) ,A61P 3/10 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
195
having an amino group
197
the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198
Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
Applicants:
RIGSHOSPITALET [DK/DK]; Blegdamsvej 9 2100 Copenhagen Ø, DK
Inventors:
BUSCHARD, Karsten; DK
HOLM, Laurits Juulskov; DK
HAUPT-JØRGENSEN, Martin; DK
Agent:
AERA A/S; Gammel Kongevej 60, 18th floor 1850 Frederiksberg C, DK
Priority Data:
PA 2017 0049008.09.2017DK
Title (EN) L-SERINE SUPPLEMENTATION IN SUBJECTS WITH PRE-DIABETES
(FR) SUPPLÉMENTATION EN L-SÉRINE CHEZ DES SUJETS PRÉDIABÉTIQUES
Abstract:
(EN) The present invention relates to supplementary dietary compositions comprising L- serine particularly for use in human subjects with pre- type 1 diabetes or other related diseases in humans to deaccelerate or prevent the progression to established type 1 diabetes. This prophylactic treatment is particularly relevant for subjects with beta-cell dysfunction and/or loss, signs of beta-cell death or presence of islet-autoantibodies. The daily dose range from about 10 mg to about 400 mg per kg bodyweight per day.
(FR) La présente invention concerne des compositions alimentaires de supplémentation comprenant de la L-sérine, en particulier destinées à être utilisées chez des sujets humains atteints de prédiabète de type 1, ou d'autres maladies associées chez l'être humain, dans le but de ralentir ou de prévenir la progression d'un diabète de type 1 établi. Ce traitement prophylactique est particulièrement pertinent pour des sujets présentant un dysfonctionnement et/ou une perte de cellules bêta, des signes de mort cellulaire des cellules bêta ou des auto-anticorps en îlots. La gamme posologique quotidienne est d'environ 10 mg à environ 400 mg par kg de poids corporel par jour.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)